



## Clinical trial results:

**Investigation of the effectiveness, tolerability and safety of ilon® Salbe classic in the treatment of acute inflammation of the hair follicle (folliculitis) - Prospective, open, evaluator-blinded, randomized, placebo-controlled multicenter trial**

**Investigation of the effectiveness, tolerability and safety of ilon® Salbe classic in the treatment of acute inflammation of the hair follicle (folliculitis) - Prospective, open, randomized, placebo-/comparator controlled multicenter trial (previous title – feasibility study)**

## Summary

EudraCT number	2016-005105-39
Trial protocol	DE
Global end of trial date	08 February 2022

## Results information

Result version number	v1 (current)
This version publication date	08 September 2023
First version publication date	08 September 2023

## Trial information

### Trial identification

Sponsor protocol code	CES ISC 001/16
-----------------------	----------------

### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

## Sponsors

Sponsor organisation name	Cesra Arzneimittel GmbH & Co.KG
Sponsor organisation address	Braunmattstraße 20, Baden-Baden, Germany, 76532
Public contact	MedWiss, Cesra Arzneimittel GmbH & Co.KG, 0049 72219540380, Christian.Zimmermann@cesra.de
Scientific contact	MedWiss, Cesra Arzneimittel GmbH & Co.KG, 0049 72219540380, Christian.Zimmermann@cesra.de

Notes:

## Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	19 January 2023
Is this the analysis of the primary completion data?	Yes
Primary completion date	08 February 2022
Global end of trial reached?	Yes
Global end of trial date	08 February 2022
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

The objective of this trial was to obtain information about the efficacy, tolerability and safety of ilon® Salbe classic (ISC) in the treatment of acute folliculitis.

Protection of trial subjects:

The trial was conducted in accordance with the principles of ICH GCP, the declaration of Helsinki, as well as all other applicable ethical and legal requirements.

Before being included in the trial, the subjects were informed in detail by the investigators about all pertinent aspects of the trial. Subjects were free to terminate their participation in the trial at any time without personal disadvantages and without giving reasons.

Any individual subject medical information obtained as a result of this trial was considered confidential and disclosure to third parties is prohibited. Subject confidentiality was further ensured by utilizing subject identification code numbers to correspond to treatment data in the computer files.

All investigational medicinal products used in this trial are already registered and commercially available. Given their quality and reliability, only very minimal risks were considered to be encountered during the trial.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	30 June 2017
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Germany: 171
Worldwide total number of subjects	171
EEA total number of subjects	171

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37	0

wk	
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	162
From 65 to 84 years	9
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

The trial was divided in two phases - a feasibility and a main study. The feasibility study was conducted with three arms (ISC, placebo, comparator) in 6 sites in Germany from Jul20217 to Mar2018. The main study was conducted with two arms (ISC, placebo) in 11 sites in Germany from Dec2019 to Feb2022.

### Pre-assignment

Screening details:

feasibility study: 70 eligible patients were randomized to either of the three treatment arms.

main study: Overall, 127 patients signed an ICF and were assessed for eligibility. 26 out of these did not satisfy the in-/exclusion criteria, and 101 were randomized into either of two treatment arms.

### Period 1

Period 1 title	overall trial (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Single blind
Roles blinded	Assessor <sup>[1]</sup>

Blinding implementation details:

Effectiveness was evaluated on the basis of the primary outcome, the change in total folliculitis lesion counts. For this, the respective treatment area was documented photographically. These photos were transferred to the CRO and analyzed centrally by independent dermatologists in a blinded manner.

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	feasibility - ISC
Arm description: -	
Arm type	Experimental
Investigational medicinal product name	ilon® Salbe classic
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Ointment
Routes of administration	Topical use

Dosage and administration details:

The individual single dose of ISC: a maximum of 2 cm cord of ointment applied twice daily, for a maximum of 7 days.

The trial medication was administered by the study site staff during each visit. At home, the trial medication was administered by the patient twice a day on the Investigator-defined treatment area.

<b>Arm title</b>	feasibility - PLAC
Arm description: -	
Arm type	Placebo
Investigational medicinal product name	Vaselin Salbe LAW, 100%
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Ointment
Routes of administration	Topical use

Dosage and administration details:

The individual single dose of placebo: a maximum of 2 cm cord of ointment applied twice daily, for a maximum of 7 days.

The trial medication was administered by the study site staff during each visit. At home, the trial

medication was administered by the patient twice a day on the Investigator-defined treatment areas.

<b>Arm title</b>	feasibility - PVI
Arm description: -	
Arm type	Active comparator
Investigational medicinal product name	Polysept® Lösung
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Cutaneous solution
Routes of administration	Topical use

**Dosage and administration details:**

The individual single dose of PVI: a maximum of 5 ml applied twice daily, for a maximum of 7 days. The trial medication was administered by the study site staff during each visit. At home, the trial medication was administered by the patient twice a day on the Investigator-defined treatment areas.

<b>Arm title</b>	main - ISC
Arm description: -	
Arm type	Experimental
Investigational medicinal product name	ilon® Salbe classic
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Ointment
Routes of administration	Topical use

**Dosage and administration details:**

The individual single dose of ISC: 2 - 3 cm cord of ointment applied twice daily on folliculitis lesions within the predefined skin area of 5x5 cm, for a maximum of 15 days. The trial medication was administered during each visit. At home, the trial medication was administered by the patient twice a day on the Investigator-defined treatment area.

<b>Arm title</b>	main - PLAC
Arm description: -	
Arm type	Placebo
Investigational medicinal product name	Vaselin Salbe LAW, 100%
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Ointment
Routes of administration	Topical use

**Dosage and administration details:**

The individual single dose of placebo: 2 - 3 cm cord of ointment applied twice daily on folliculitis lesions within the predefined skin area of 5x5 cm, for a maximum of 15 days. The trial medication was administered by the study site staff during each visit. At home, the trial medication was administered by the patient twice a day on the Investigator-defined treatment areas.

**Notes:**

[1] - The roles blinded appear inconsistent with a simple blinded trial.

Justification: This clinical trials was conducted as open trial, i.e. investigators, patients etc. were aware of the treatment allocation. The assessment of the photographic documentation was performed centrally by independent persons - and these were blinded.

<b>Number of subjects in period 1</b>	feasibility - ISC	feasibility - PLAC	feasibility - PVI
Started	21	25	24
Completed	21	25	23
Not completed	0	0	1
premature healing	-	-	1
Adverse event, non-fatal	-	-	-
Lost to follow-up	-	-	-
Lack of efficacy	-	-	-

<b>Number of subjects in period 1</b>	main - ISC	main - PLAC
Started	50	51
Completed	47	48
Not completed	3	3
premature healing	-	1
Adverse event, non-fatal	2	-
Lost to follow-up	1	1
Lack of efficacy	-	1

## Baseline characteristics

### Reporting groups

Reporting group title	feasibility - ISC
Reporting group description: -	
Reporting group title	feasibility - PLAC
Reporting group description: -	
Reporting group title	feasibility - PVI
Reporting group description: -	
Reporting group title	main - ISC
Reporting group description: -	
Reporting group title	main - PLAC
Reporting group description: -	

Reporting group values	feasibility - ISC	feasibility - PLAC	feasibility - PVI
Number of subjects	21	25	24
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	0	0	0
From 65-84 years	0	0	0
85 years and over	0	0	0
18-69 years	20	24	22
70-75 years	1	1	2
Gender categorical			
Units: Subjects			
Female	11	11	14
Male	10	14	10

Reporting group values	main - ISC	main - PLAC	Total
Number of subjects	50	51	171
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	0	0	0
From 65-84 years	0	0	0

85 years and over	0	0	0
18-69 years	49	50	165
70-75 years	1	1	6
Gender categorical			
Units: Subjects			
Female	26	30	92
Male	24	21	79



## End points

### End points reporting groups

Reporting group title	feasibility - ISC
Reporting group description: -	
Reporting group title	feasibility - PLAC
Reporting group description: -	
Reporting group title	feasibility - PVI
Reporting group description: -	
Reporting group title	main - ISC
Reporting group description: -	
Reporting group title	main - PLAC
Reporting group description: -	

### Primary: main - change in total follicle lesion counts from Day 1 to the day of study completion

End point title	main - change in total follicle lesion counts from Day 1 to the day of study completion <sup>[1]</sup>
End point description: main study - change in total follicle lesion counts from Day 1 to the day of study completion (ITT population)	
End point type	Primary
End point timeframe: main study: from Day 1 to the day of study completion	

Notes:

[1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The clinical trial was divided in two phases - a feasibility and a main study. As the system did not allow creation of two separate study periods to distinguish between feasibility and main study, both parts have been documented as one (overall) but with a total of 5 treatment arms (3x for feasibility and 2x for main study). Analyses have been conducted separately, though. Consequently, statistics are only available and provided for the respective study part.

End point values	main - ISC	main - PLAC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	49	51		
Units: change in number of follicle lesions				
arithmetic mean (standard deviation)	-1.7 (± 4.51)	-2.2 (± 3.66)		

### Statistical analyses

Statistical analysis title	ISC - superiority
Statistical analysis description: ISC will be compared to Placebo using ANOVA adjusted for day 1 values.	
Comparison groups	main - ISC v main - PLAC

Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2723
Method	ANOVA
Parameter estimate	Mean difference (final values)
Point estimate	-0.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2
upper limit	0.6
Variability estimate	Standard deviation
Dispersion value	3.2

### Primary: feasibility - change in follicle lesion counts from Day 0 to the Final Visit

End point title	feasibility - change in follicle lesion counts from Day 0 to the Final Visit <sup>[2]</sup>
End point description:	feasibility study - change in follicle lesion counts from Day 0 to the Final Visit (subjects with evaluable photographic documentation)
End point type	Primary
End point timeframe:	feasibility study - from Day 0 to the Final Visit

#### Notes:

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The clinical trial was divided in two phases - a feasibility and a main study. As the system did not allow creation of two separate study periods to distinguish between feasibility and main study, both parts have been documented as one (overall) but with a total of 5 treatment arms (3x for feasibility and 2x for main study). Analyses have been conducted separately, though. Consequently, statistics are only available and provided for the respective study part.

End point values	feasibility - ISC	feasibility - PLAC	feasibility - PVI	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	16 <sup>[3]</sup>	17 <sup>[4]</sup>	15 <sup>[5]</sup>	
Units: change in number of follicle lesions				
arithmetic mean (standard deviation)	-0.9 (± 5.25)	0.4 (± 3.83)	-1.3 (± 5.86)	

#### Notes:

[3] - subjects with evaluable photographic documentation

[4] - subjects with evaluable photographic documentation

[5] - subjects with evaluable photographic documentation

### Statistical analyses

Statistical analysis title	feasibility - superiority ISC vs. PLAC
Statistical analysis description:	feasibility study - Superiority of ISC to placebo was analyzed using ANOVA adjusted for Day 0 values.
Comparison groups	feasibility - ISC v feasibility - PLAC

Number of subjects included in analysis	33
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5243
Method	ANOVA
Parameter estimate	Mean difference (final values)
Point estimate	0.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.9
upper limit	3.6
Variability estimate	Standard deviation
Dispersion value	3.8

### Primary: feasibility - improvement

End point title	feasibility - improvement <sup>[6]</sup>
End point description:	feasibility study - improvement; subjects with reduction in number of follicle lesions by at least one count (subjects with evaluable photographic documentation)
End point type	Primary
End point timeframe:	feasibility study - from Day 0 to the Final Visit

Notes:

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The clinical trial was divided in two phases - a feasibility and a main study. As the system did not allow creation of two separate study periods to distinguish between feasibility and main study, both parts have been documented as one (overall) but with a total of 5 treatment arms (3x for feasibility and 2x for main study). Analyses have been conducted separately, though. Consequently, statistics are only available and provided for the respective study part.

End point values	feasibility - ISC	feasibility - PLAC	feasibility - PVI	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	16 <sup>[7]</sup>	17 <sup>[8]</sup>	15 <sup>[9]</sup>	
Units: number of subjects with improvement	9	3	10	

Notes:

[7] - subjects with evaluable photographic documentation

[8] - subjects with evaluable photographic documentation

[9] - subjects with evaluable photographic documentation

### Statistical analyses

Statistical analysis title	feasibility - improvement rate ISC vs. PLAC
Comparison groups	feasibility - ISC v feasibility - PLAC

Number of subjects included in analysis	33
Analysis specification	Pre-specified
Analysis type	other
Method	Wald
Parameter estimate	rate difference
Point estimate	-38.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-68.92
upper limit	-8.28

## Secondary: feasibility - general assessment according to observers

End point title	feasibility - general assessment according to observers <sup>[10]</sup>
End point description:	feasibility study - Observers (blinded) gave an overall assessment of treatment success based on photographs
End point type	Secondary
End point timeframe:	feasibility study - from Day 0 to the Final Visit

Notes:

[10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The clinical trial was divided in two phases - a feasibility and a main study. As the system did not allow creation of two separate study periods to distinguish between feasibility and main study, both parts have been documented as one (overall) but with a total of 5 treatment arms (3x for feasibility and 2x for main study). Analyses have been conducted separately, though. Consequently, statistics are only available and provided for the respective study part.

End point values	feasibility - ISC	feasibility - PLAC	feasibility - PVI	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	21 <sup>[11]</sup>	25 <sup>[12]</sup>	24 <sup>[13]</sup>	
Units: number of subjects				
worse	2	4	4	
unchanged	5	10	12	
improved	14	11	8	

Notes:

[11] - ITT population

[12] - ITT population

[13] - ITT population

## Statistical analyses

Statistical analysis title	feasibility - general assessment ISC vs. PLAC
Comparison groups	feasibility - ISC v feasibility - PLAC

Number of subjects included in analysis	46
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.149
Method	Fisher exact

<b>Statistical analysis title</b>	feasibility - general assessment ISC vs. PVI
Comparison groups	feasibility - ISC v feasibility - PVI
Number of subjects included in analysis	45
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.038
Method	Fisher exact

### Secondary: feasibility - course of total follicle lesion counts

End point title	feasibility - course of total follicle lesion counts <sup>[14]</sup>
End point description: feasibility study - course of total follicle lesion counts assessed by subjects' daily photographic documentation (ITT population)	
End point type	Secondary
End point timeframe: feasibility study - from Day 0 to the Final Visit	

Notes:

[14] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The clinical trial was divided in two phases - a feasibility and a main study. As the system did not allow creation of two separate study periods to distinguish between feasibility and main study, both parts have been documented as one (overall) but with a total of 5 treatment arms (3x for feasibility and 2x for main study). Analyses have been conducted separately, though. Consequently, statistics are only available and provided for the respective study part.

End point values	feasibility - ISC	feasibility - PLAC	feasibility - PVI	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	21 <sup>[15]</sup>	25 <sup>[16]</sup>	24 <sup>[17]</sup>	
Units: number of follicle lesions				
arithmetic mean (standard deviation)				
day 0	5.2 (± 4.85)	4.3 (± 3.07)	5.3 (± 5.65)	
day 1	5.0 (± 4.13)	5.9 (± 5.84)	4.0 (± 3.57)	
day 2	5.4 (± 5.90)	5.0 (± 5.21)	3.4 (± 3.15)	
day 3	4.9 (± 5.01)	5.3 (± 7.00)	3.2 (± 2.44)	
day 4	4.8 (± 4.11)	5.3 (± 4.19)	3.1 (± 2.26)	
day 5	3.4 (± 3.69)	5.9 (± 5.05)	2.7 (± 1.67)	
day 6	2.6 (± 2.16)	3.9 (± 3.17)	3.3 (± 2.31)	
day 7	1.3 (± 1.34)	3.3 (± 3.25)	3.6 (± 3.05)	

Notes:

[15] - ITT population

[16] - ITT population

[17] - ITT population

## Statistical analyses

No statistical analyses for this end point

### Secondary: feasibility - final assessment of the study medication

End point title	feasibility - final assessment of the study medication <sup>[18]</sup>
-----------------	--

End point description:

feasibility study - The study medication was finally assessed by the subjects with respect to different parameters (rating scale 0-10) (ITT population)

End point type	Secondary
----------------	-----------

End point timeframe:

feasibility study - Final Visit

Notes:

[18] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The clinical trial was divided in two phases - a feasibility and a main study. As the system did not allow creation of two separate study periods to distinguish between feasibility and main study, both parts have been documented as one (overall) but with a total of 5 treatment arms (3x for feasibility and 2x for main study). Analyses have been conducted separately, though. Consequently, statistics are only available and provided for the respective study part.

End point values	feasibility - ISC	feasibility - PLAC	feasibility - PVI	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	21 <sup>[19]</sup>	25 <sup>[20]</sup>	24 <sup>[21]</sup>	
Units: value according to rating scale				
arithmetic mean (standard deviation)				
General effectiveness	5.8 (± 2.98)	3.7 (± 2.99)	6.3 (± 2.77)	
Impact on pain	5.9 (± 2.70)	4.0 (± 3.11)	5.9 (± 3.24)	
Application sensation	8.0 (± 2.79)	7.3 (± 2.79)	7.4 (± 2.95)	
Distributability	8.3 (± 2.55)	7.7 (± 2.62)	7.5 (± 3.12)	
Skin sensation	8.2 (± 2.68)	7.2 (± 2.74)	7.6 (± 2.39)	
Smell	8.3 (± 2.33)	7.8 (± 2.50)	6.8 (± 3.12)	
Color	6.8 (± 2.77)	8.0 (± 1.99)	4.3 (± 3.04)	
Skin compatibility	8.5 (± 2.56)	9.0 (± 2.05)	8.9 (± 1.88)	

Notes:

[19] - ITT population

[20] - ITT population

[21] - ITT population

## Statistical analyses

Statistical analysis title	feasibility - general effectiveness ISC vs. PLAC
----------------------------	--

Comparison groups	feasibility - ISC v feasibility - PLAC
-------------------	--

Number of subjects included in analysis	46
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.029
Method	Wilcoxon (Mann-Whitney)

<b>Statistical analysis title</b>	feasibility - general effectiveness ISC vs. PVI
Comparison groups	feasibility - ISC v feasibility - PVI
Number of subjects included in analysis	45
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.589
Method	Wilcoxon (Mann-Whitney)

<b>Statistical analysis title</b>	feasibility - impact on pain ISC vs. PLAC
Comparison groups	feasibility - ISC v feasibility - PLAC
Number of subjects included in analysis	46
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.077
Method	Wilcoxon (Mann-Whitney)

<b>Statistical analysis title</b>	feasibility - impact on pain ISC vs. PVI
Comparison groups	feasibility - ISC v feasibility - PVI
Number of subjects included in analysis	45
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.966
Method	Wilcoxon (Mann-Whitney)

<b>Statistical analysis title</b>	feasibility - application sensation ISC vs. PLAC
Comparison groups	feasibility - ISC v feasibility - PLAC
Number of subjects included in analysis	46
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.279
Method	Wilcoxon (Mann-Whitney)

<b>Statistical analysis title</b>	feasibility - application sensation ISC vs. PVI
Comparison groups	feasibility - ISC v feasibility - PVI
Number of subjects included in analysis	45
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.303
Method	Wilcoxon (Mann-Whitney)

<b>Statistical analysis title</b>	feasibility - distributability ISC vs. PLAC
Comparison groups	feasibility - ISC v feasibility - PLAC
Number of subjects included in analysis	46
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.506
Method	Wilcoxon (Mann-Whitney)

<b>Statistical analysis title</b>	feasibility - distributability ISC vs. PVI
Comparison groups	feasibility - ISC v feasibility - PVI
Number of subjects included in analysis	45
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.366
Method	Wilcoxon (Mann-Whitney)

<b>Statistical analysis title</b>	feasibility - skin sensation ISC vs. PLAC
Comparison groups	feasibility - ISC v feasibility - PLAC
Number of subjects included in analysis	46
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.154
Method	Wilcoxon (Mann-Whitney)

<b>Statistical analysis title</b>	feasibility - skin sensation ISC vs. PVI
Comparison groups	feasibility - ISC v feasibility - PVI
Number of subjects included in analysis	45
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.214
Method	Wilcoxon (Mann-Whitney)



<b>Statistical analysis title</b>	feasibility - smell ISC vs. PLAC
Comparison groups	feasibility - ISC v feasibility - PLAC
Number of subjects included in analysis	46
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.686
Method	Wilcoxon (Mann-Whitney)

<b>Statistical analysis title</b>	feasibility - smell ISC vs. PVI
Comparison groups	feasibility - ISC v feasibility - PVI
Number of subjects included in analysis	45
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.147
Method	Wilcoxon (Mann-Whitney)

<b>Statistical analysis title</b>	feasibility - color ISC vs. PLAC
Comparison groups	feasibility - ISC v feasibility - PLAC
Number of subjects included in analysis	46
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.153
Method	Wilcoxon (Mann-Whitney)

<b>Statistical analysis title</b>	feasibility - color ISC vs. PVI
Comparison groups	feasibility - ISC v feasibility - PVI
Number of subjects included in analysis	45
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.009
Method	Wilcoxon (Mann-Whitney)

<b>Statistical analysis title</b>	feasibility - skin compatibility ISC vs. PLAC
Comparison groups	feasibility - ISC v feasibility - PLAC

Number of subjects included in analysis	46
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.396
Method	Wilcoxon (Mann-Whitney)

<b>Statistical analysis title</b>	feasibility - skin compatibility ISC vs. PVI
Comparison groups	feasibility - ISC v feasibility - PVI
Number of subjects included in analysis	45
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.959
Method	Wilcoxon (Mann-Whitney)

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

from when the subject signed the Informed Consent to the end of subject's participation

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	25.0
--------------------	------

### Reporting groups

Reporting group title	feasibility - ISC
-----------------------	-------------------

Reporting group description: -

Reporting group title	feasibility - PLAC
-----------------------	--------------------

Reporting group description: -

Reporting group title	feasibility - PVI
-----------------------	-------------------

Reporting group description: -

Reporting group title	main - ISC
-----------------------	------------

Reporting group description: -

Reporting group title	main - PLAC
-----------------------	-------------

Reporting group description: -

Serious adverse events	feasibility - ISC	feasibility - PLAC	feasibility - PVI
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 21 (0.00%)	0 / 25 (0.00%)	0 / 24 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0

Serious adverse events	main - ISC	main - PLAC	
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 50 (0.00%)	0 / 51 (0.00%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	feasibility - ISC	feasibility - PLAC	feasibility - PVI
Total subjects affected by non-serious adverse events			
subjects affected / exposed	3 / 21 (14.29%)	2 / 25 (8.00%)	2 / 24 (8.33%)

Nervous system disorders			
Headache			
subjects affected / exposed	0 / 21 (0.00%)	0 / 25 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
Influenza like illness			
subjects affected / exposed	0 / 21 (0.00%)	0 / 25 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Application site hypersensitivity			
subjects affected / exposed	0 / 21 (0.00%)	0 / 25 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Application site irritation			
subjects affected / exposed	0 / 21 (0.00%)	0 / 25 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Application site pruritus			
subjects affected / exposed	2 / 21 (9.52%)	1 / 25 (4.00%)	0 / 24 (0.00%)
occurrences (all)	2	1	0
Application site erythema			
subjects affected / exposed	0 / 21 (0.00%)	1 / 25 (4.00%)	0 / 24 (0.00%)
occurrences (all)	0	1	0
Contact dermatitis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 25 (0.00%)	1 / 24 (4.17%)
occurrences (all)	0	0	1
Reddening			
subjects affected / exposed	0 / 21 (0.00%)	0 / 25 (0.00%)	2 / 24 (8.33%)
occurrences (all)	0	0	2
Gastrointestinal disorders			
Diarrhea	Additional description: Nausea		
subjects affected / exposed	1 / 21 (4.76%)	0 / 25 (0.00%)	0 / 24 (0.00%)
occurrences (all)	1	0	0
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 25 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0

<b>Non-serious adverse events</b>	main - ISC	main - PLAC	
Total subjects affected by non-serious adverse events			

subjects affected / exposed	4 / 50 (8.00%)	1 / 51 (1.96%)	
Nervous system disorders			
Headache			
subjects affected / exposed	0 / 50 (0.00%)	1 / 51 (1.96%)	
occurrences (all)	0	1	
General disorders and administration site conditions			
Influenza like illness			
subjects affected / exposed	1 / 50 (2.00%)	0 / 51 (0.00%)	
occurrences (all)	1	0	
Application site hypersensitivity			
subjects affected / exposed	1 / 50 (2.00%)	0 / 51 (0.00%)	
occurrences (all)	1	0	
Application site irritation			
subjects affected / exposed	1 / 50 (2.00%)	0 / 51 (0.00%)	
occurrences (all)	1	0	
Application site pruritus			
subjects affected / exposed	1 / 50 (2.00%)	0 / 51 (0.00%)	
occurrences (all)	1	0	
Application site erythema			
subjects affected / exposed	1 / 50 (2.00%)	0 / 51 (0.00%)	
occurrences (all)	1	0	
Contact dermatitis			
subjects affected / exposed	0 / 50 (0.00%)	0 / 51 (0.00%)	
occurrences (all)	0	0	
Reddening			
subjects affected / exposed	0 / 50 (0.00%)	0 / 51 (0.00%)	
occurrences (all)	0	0	
Gastrointestinal disorders			
Diarrhea	Additional description: Nausea		
subjects affected / exposed	0 / 50 (0.00%)	0 / 51 (0.00%)	
occurrences (all)	0	0	
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	1 / 50 (2.00%)	1 / 51 (1.96%)	
occurrences (all)	1	1	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
05 November 2019	Version 2.0 (2.1) switch from feasibility to main study
24 July 2020	Version 3.0 Prolongation of recruitment period
11 May 2021	Version 4.0 Prolongation of recruitment period

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? Yes

Date	Interruption	Restart date
18 March 2020	As it could not be excluded that Corona situation and resulting restrictions have an impact on protocol compliant conduct of the clinical trial, recruitment of new study participants was temporarily stopped.	14 May 2020

Notes:

### Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

- treatment duration: 7d (feasibility) vs. 14 d (main)
- observations in main study were limited to d7 and d14 with no additional visits planned in-between
- evaluation of photographic material less accurate as in person at medical visit

Notes: